Generating AI summary…

Transgene jumps 20% on positive cancer vaccine data in early trial

Sept 3 (Reuters) - Transgene shares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported positive Phase 1 trial data on its vaccine candidate for head and neck cancer. Investors have rewarded encouraging data from other personalised cancer-vaccine programmes as well: Moderna shares more than doubled after its melanoma vaccine data showed a reduction in continue reading...